히알루론산 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 지역별, 부문별 예측(2025-2030년)

Hyaluronic Acid Market Growth & Trends:

The global hyaluronic acid market size is expected to reach USD 16.7 billion by 2030, registering a CAGR of 7.81% from 2025 to 2030, according to a new report by Grand View Research, Inc. Factors, such as increasing concern of population regarding chemicals, desire to get quick and evident results, and shorter recovery time are high impact rendering drivers. The industry is evolving rapidly due to the increasing adoption of aesthetic procedures in developed and developing regions. Increasing the use of hyaluronic acid surfaces in cardiovascular implants, such as stents and vascular grafts, for improving compatibility coupled with the growing awareness about anti-aging products is fueling the growth.

The efficacy and evident results of hyaluronic acid-based dermal fillers are attracting this population base. Furthermore, the COVID-19 pandemic has changed the dynamics of many industries, with movement restrictions, social distancing, and revised practices becoming the "new normal." As the cosmetic industry is gradually resuming its operations, a number of doctors have reported a significant increase in inquiries for aesthetic surgeries. Moreover, the lockdown has encouraged all professionals to use video-conferencing facilities, which has made people more conscious of their looks. In some cases, it has led people to opt for cosmetic treatments; this is termed the "Zoom Boom" or the "Zoom effect."

Cosmetic surgeons across the world have witnessed a significant increase in the number of patients as a result of the pandemic, particularly in countries, such as the U.S., Australia, and Japan. North America held the maximum revenue share in 2022. Preference for short-treatment regimens, even though high-priced, and the prevalence of target diseases, such as osteoarthritis, are the key factors attributed to the high share. In 2022, the most lucrative product applications in the North America region were in the form of dermal fillers and viscos supplements for the management of osteoarthritis. Asia Pacific is anticipated to register the fastest CAGR during the forecast period.

The growing geriatric population in China and Japan provide a large customer base for anti-aging products and services. Rising awareness about product applications and efficacy also fuels the demand. In addition, increasing disposable income levels are further supporting the region's expansion. Europe has undergone impressive changes over the last 2 years. The growing demand is witnessing increasing price competition owing to new entrants. The WHO recently announced the obesity epidemic in the U.K. and Germany. The relationship between the increasing aging population and obesity is a potential driver for the Europe regional sector

Hyaluronic Acid Market Report Highlights:

• The dermal fillers segment dominated the market and obtained the largest revenue share of 41.82% in 2024.
• North America dominated the market and accounted for 42.08% share in 2024. The hyaluronic acid market is driven by increasing demand for anti-aging treatments, rising osteoarthritis cases, and growing awareness of minimally invasive procedures.
• The U.S. hyaluronic acid market is experiencing robust growth, driven by increasing demand for non-surgical aesthetic procedures and advancements in medical applications, particularly hyaluronic acid-based dermal fillers.
• APAC hyaluronic acid market is anticipated grow with a CAGR of 8.25% over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Regional scope
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
• 1.8. List of Secondary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Hyaluronic Acid Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Hyaluronic Acid Market: Application Estimates & Trend Analysis

• 4.1. Application Market Share, 2024 & 2030
• 4.2. Application Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analyses, By Application, 2018 to 2030
  • 4.3.1. Dermal fillers
    • 4.3.1.1. Dermal fillers Market 2018 - 2030 (USD Million)
  • 4.3.2. Osteoarthritis
    • 4.3.2.1. Osteoarthritis Market 2018 to 2030 (USD Million)
    • 4.3.2.2. Single-injection
      • 4.4.2.2.1 Single injection Market 2018 to 2030 (USD Million)
    • 4.3.2.3. Three-injection
      • 4.4.2.3.1. Three injection Market 2018 to 2030 (USD Million)
    • 4.3.2.4. Five-injection
      • 4.4.2.3.1. Five injection Market 2018 to 2030 (USD Million)
  • 4.4.3. Ophthalmic
    • 4.4.3.3. Ophthalmic Market 2018 to 2030 (USD Million)
  • 4.4.4. Vesicoureteral reflux
    • 4.4.2.3. Vesicoureteral reflux Market 2018 to 2030 (USD Million)

Chapter 5. Hyaluronic Acid Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Share Analysis, 2024 & 2030
• 5.2. Regional Market Dashboard
• 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.4. North America
  • 5.5.1. North America Hyaluronic Acid Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 5.5.2. U.S.
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework/
    • 5.5.1.3. Reimbursement structure
    • 5.5.1.4. U.S. Hyaluronic Acid market 2018 to 2030 (USD Million)
  • 5.5.3. Canada
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework
    • 5.5.1.3. Reimbursement structure
    • 5.5.1.4. Canada Hyaluronic Acid market 2018 to 2030 (USD Million)
  • 5.5.4. Mexico
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework
    • 5.5.1.3. Reimbursement structure
    • 5.5.1.4. Mexico Hyaluronic Acid market 2018 to 2030 (USD Million)
• 5.5. Europe
  • 5.5.1. Europe Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. UK
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Regulatory Framework
    • 5.5.2.3. Reimbursement Framework
    • 5.5.2.4. UK Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Germany
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Regulatory Framework
    • 5.5.3.3. Reimbursement Framework
    • 5.5.3.4. Germany Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. France
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Regulatory Framework
    • 5.5.4.3. Reimbursement Framework
    • 5.5.4.4. France Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.5. Italy
    • 5.5.5.1. Key Country Dynamics
    • 5.5.5.2. Regulatory Framework
    • 5.5.5.3. Reimbursement Framework
    • 5.5.5.4. Italy Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.6. Spain
    • 5.5.6.1. Key Country Dynamics
    • 5.5.6.2. Regulatory Framework
    • 5.5.6.3. Reimbursement Framework
    • 5.5.6.4. Spain Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.7. Denmark
    • 5.5.7.1. Key Country Dynamics
    • 5.5.7.2. Regulatory Framework
    • 5.5.7.3. Reimbursement Framework
    • 5.5.7.4. Denmark Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.8. Sweden
    • 5.5.8.1. Key Country Dynamics
    • 5.5.8.2. Regulatory Framework
    • 5.5.8.3. Reimbursement Framework
    • 5.5.8.4. Sweden Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.9. Norway
    • 5.5.9.1. Key Country Dynamics
    • 5.5.9.2. Regulatory Framework
    • 5.5.9.3. Reimbursement Framework
    • 5.5.9.4. Norway Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.2. Japan
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Regulatory Framework
    • 5.6.2.3. Reimbursement Framework
    • 5.6.2.4. Japan Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. China
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Regulatory Framework
    • 5.6.3.3. Reimbursement Framework
    • 5.6.3.4. China Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. India
    • 5.6.4.1. Key Country Dynamics
    • 5.6.4.2. Regulatory Framework
    • 5.6.4.3. Reimbursement Framework
    • 5.6.4.4. India Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. Australia
    • 5.6.5.1. Key Country Dynamics
    • 5.6.5.2. Regulatory Framework
    • 5.6.5.3. Reimbursement Framework
    • 5.6.5.4. Australia Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.6. South Korea
    • 5.6.6.1. Key Country Dynamics
    • 5.6.6.2. Regulatory Framework
    • 5.6.6.3. Reimbursement Framework
    • 5.6.6.4. South Korea Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.7. Thailand
    • 5.6.7.1. Key Country Dynamics
    • 5.6.7.2. Regulatory Framework
    • 5.6.7.3. Reimbursement Framework
    • 5.6.7.4. Thailand Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Latin America
  • 5.7.1. Latin America Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7.2. Brazil
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Regulatory Framework
    • 5.7.2.3. Reimbursement Framework
    • 5.7.2.4. Japan Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7.3. Argentina
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Regulatory Framework
    • 5.7.3.3. Reimbursement Framework
    • 5.7.3.4. China Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Middle East and Africa
  • 5.8.1. Middle East and Africa Hyaluronic Acid Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 5.8.2. South Africa
    • 5.8.2.1. Key Country Dynamics
    • 5.8.2.2. Regulatory Framework
    • 5.8.2.3. Reimbursement Framework
    • 5.8.2.4. South Africa Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key Country Dynamics
    • 5.8.3.2. Regulatory Framework
    • 5.8.3.3. Reimbursement Framework
    • 5.8.3.4. Saudi Arabia Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8.4. UAE
    • 5.8.4.1. Key Country Dynamics
    • 5.8.4.2. Regulatory Framework
    • 5.8.4.3. Reimbursement Framework
    • 5.8.4.4. UAE Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key Country Dynamics
    • 5.8.5.2. Regulatory Framework
    • 5.8.5.3. Reimbursement Framework
    • 5.8.5.4. Kuwait Hyaluronic Acid Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listings
  • 6.5.1. Allergan
    • 6.5.1.1. Company overview
    • 6.5.1.2. Financial performance
    • 6.5.1.3. Product benchmarking
    • 6.5.1.4. Strategic initiatives
  • 6.5.2. Sanofi
    • 6.5.2.1. Company overview
    • 6.5.2.2. Financial performance
    • 6.5.2.3. Product benchmarking
    • 6.5.2.4. Strategic initiatives
  • 6.5.3. Genzyme Corporation
    • 6.5.3.1. Company overview
    • 6.5.3.2. Financial performance
    • 6.5.3.3. Product benchmarking
    • 6.5.3.4. Strategic initiatives
  • 6.5.4. Anika Therapeutics, Inc.
    • 6.5.4.1. Company overview
    • 6.5.4.2. Financial performance
    • 6.5.4.3. Product benchmarking
    • 6.5.4.4. Strategic initiatives
  • 6.5.5. Salix Pharmaceuticals
    • 6.5.5.1. Company overview
    • 6.5.5.2. Financial performance
    • 6.5.5.3. Product benchmarking
    • 6.5.5.4. Strategic initiatives
  • 6.5.6. Seikagaku Corporation
    • 6.5.6.1. Company overview
    • 6.5.6.2. Financial performance
    • 6.5.6.3. Product benchmarking
    • 6.5.6.4. Strategic initiatives
  • 6.5.7. F. Hoffmann-La Roche Ag
    • 6.5.7.1. Company overview
    • 6.5.7.2. Financial performance
    • 6.5.7.3. Product benchmarking
    • 6.5.7.4. Strategic initiatives
  • 6.5.8. Galderma Laboratories L.P.
    • 6.5.8.1. Company overview
    • 6.5.8.2. Financial performance
    • 6.5.8.3. Product benchmarking
    • 6.5.8.4. Strategic initiatives
  • 6.5.9. Zimmer Biomet
    • 6.5.9.1. Company overview
    • 6.5.9.2. Financial performance
    • 6.5.9.3. Product benchmarking
    • 6.5.9.4. Strategic initiatives
  • 6.5.10. Smith & Nephew Plc
    • 6.5.10.1. Company overview
    • 6.5.10.2. Financial performance
    • 6.5.10.3. Product benchmarking
    • 6.5.10.4. Strategic initiatives
  • 6.5.11. Ferring B.V.
    • 6.5.11.1. Company overview
    • 6.5.11.2. Financial performance
    • 6.5.11.3. Product benchmarking
    • 6.5.11.4. Strategic initiatives
  • 6.5.12. Lifecore Biomedical, Llc
    • 6.5.12.1. Company overview
    • 6.5.12.2. Financial performance
    • 6.5.12.3. Product benchmarking
    • 6.5.12.4. Strategic initiatives
  • 6.5.13. HTL Biotechnology
    • 6.5.13.1. Company overview
    • 6.5.13.2. Financial performance
    • 6.5.13.3. Product benchmarking
    • 6.5.13.4. Strategic initiatives
  • 6.5.14. Shiseido Company, Limited
    • 6.5.14.1. Company overview
    • 6.5.14.2. Financial performance
    • 6.5.14.3. Product benchmarking
    • 6.5.14.4. Strategic initiatives
  • 6.5.15. Bloomage Biotechnology Corporation Limited
    • 6.5.15.1. Company overview
    • 6.5.15.2. Financial performance
    • 6.5.15.3. Product benchmarking
    • 6.5.15.4. Strategic initiatives
  • 6.5.16. LG Life Sciences Ltd (LG Chem.)
    • 6.5.16.1. Company overview
    • 6.5.16.2. Financial performance
    • 6.5.16.3. Product benchmarking
    • 6.5.16.4. Strategic initiatives
  • 6.5.17. Maruha Nichiro, Inc.
    • 6.5.17.1. Company overview
    • 6.5.17.2. Financial performance
    • 6.5.17.3. Product benchmarking
    • 6.5.17.4. Strategic initiatives